Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov;17(6):977-82.
doi: 10.4103/2230-8210.122602.

Management of statin intolerance

Soma B Raju  1 , Kiron Varghese  2 , K Madhu  3
Affiliations

Management of statin intolerance

Soma B Raju et al. Indian J Endocrinol Metab. 2013 Nov.

Abstract

Statins are the revolutionary drugs in the cardiovascular pharmacotherapy. But they also possess several adverse effects like myopathy with elevation of hepatic transaminases (>3 times the upper limit of normal) or creatine kinase (>10 times the upper limit of normal) and some rare side-effects, including peripheral neuropathy, memory loss, sleep disturbances, and erectile dysfunction. Due to these adverse effects, patients abruptly withdrew statins without consulting physicians. This abrupt discontinuation of statins is termed as statin intolerance. Statin-induced myopathy constitutes two third of all side-effects from statins and is the primary reason for statin intolerance. Though statin intolerance has considerably impacted cardiovascular outcomes in the high-risk patients, it has been well effectively managed by prescribing statins either as alternate-day or once weekly dosage regimen, as combination therapy with a non-statin therapy or and by dietary intervention. The present article reviews the causes, clinical implications of statin withdrawal and management of statin intolerance.

Keywords: Adverse effects of stains; myopathy; rhabdomyolysis; statin intolerance; statins.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Statin-induce myopathy management
See this image and copyright information in PMC

References

    1. Gotto AM. Statins, cardiovascular disease, and drug safety. Am J Cardiol. 2006;97:3C–5. - PubMed
    1. Abd TT, Jacobson TA. Statin induced myopathy: A review and myopathy. Expert Opin Drug Saf. 2011;10:373–87. - PubMed
    1. Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins-mechanism and consequences. Curr Drug Saf. 2009;4:209–28. - PubMed
    1. Stone NJ. Stopping statins. Circulation. 2004;110:2280–2. - PubMed
    1. Kalra S, Agrawal N, Kalra B, Sharma A, Kamboj R. The role of Coenzyme Q10 in statin associated myopathy. Electron Physic. 2009;1:2–8.